Total Payments
$15,734
2024 Payments
$104.77
Companies
81
Transactions
819
Medicare Patients
3,238
Medicare Billing
$920,681
Payment Breakdown by Category
Food & Beverage$15,307 (97.3%)
Education$427.14 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,307 | 797 | 97.3% |
| Education | $427.14 | 22 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,198 | 92 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,165 | 67 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $945.64 | 50 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $882.95 | 50 | $0 (2021) |
| Amgen Inc. | $814.19 | 31 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $704.69 | 29 | $0 (2021) |
| PFIZER INC. | $703.70 | 50 | $0 (2021) |
| Genentech USA, Inc. | $645.90 | 41 | $0 (2020) |
| Eisai Inc. | $439.48 | 20 | $0 (2021) |
| Octapharma USA, Inc. | $428.26 | 10 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $104.77 | 5 | GlaxoSmithKline, LLC. ($40.35) |
| 2023 | $126.23 | 4 | E.R. Squibb & Sons, L.L.C. ($76.52) |
| 2022 | $189.11 | 4 | Janssen Scientific Affairs, LLC ($140.53) |
| 2021 | $1,088 | 53 | AstraZeneca Pharmaceuticals LP ($140.67) |
| 2020 | $3,168 | 156 | Merck Sharp & Dohme Corporation ($325.62) |
| 2019 | $3,720 | 211 | E.R. Squibb & Sons, L.L.C. ($244.40) |
| 2018 | $3,265 | 181 | Novartis Pharmaceuticals Corporation ($375.44) |
| 2017 | $4,073 | 205 | Novartis Pharmaceuticals Corporation ($459.88) |
All Payment Transactions
819 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/24/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $29.29 | General |
| 10/03/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $13.36 | General |
| Category: Oncology | ||||||
| 09/25/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Oncology | ||||||
| 10/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $26.51 | General |
| Category: ONCOLOGY | ||||||
| 08/25/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: Oncology | ||||||
| 08/21/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $27.93 | General |
| Category: Oncology | ||||||
| 03/17/2023 | E.R. Squibb & Sons, L.L.C. | ABILIFY (Drug) | Education | In-kind items and services | $48.59 | General |
| Category: Neuroscience | ||||||
| 12/23/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.82 | General |
| Category: Oncology | ||||||
| 12/22/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $25.76 | General |
| Category: Oncology | ||||||
| 09/13/2022 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $113.45 | General |
| Category: Oncology | ||||||
| 09/12/2022 | Janssen Scientific Affairs, LLC | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $27.08 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/07/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: Oncology | ||||||
| 05/04/2021 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $29.28 | General |
| Category: Oncology | ||||||
| 05/03/2021 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO, RETEVMO | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: Oncology | ||||||
| 04/29/2021 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Oncology | ||||||
| 04/28/2021 | AMAG Pharmaceuticals, Inc. | FERAHEME (Drug) | Food and Beverage | In-kind items and services | $31.71 | General |
| Category: For the treatment of iron deficiency anemia associated with chronic kidney disease | ||||||
| 04/27/2021 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $18.79 | General |
| Category: Oncology | ||||||
| 04/26/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $28.77 | General |
| Category: ONCOLOGY | ||||||
| 04/22/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: Oncology | ||||||
| 04/21/2021 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: ONCOLOGY | ||||||
| 04/16/2021 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Oncology | ||||||
| 04/15/2021 | Dova Pharmaceuticals | Doptelet (Drug) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Hematology/Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 366 | 3,758 | $242,280 | $96,028 |
| 2022 | 14 | 555 | 5,215 | $318,130 | $117,312 |
| 2021 | 26 | 831 | 34,128 | $735,495 | $256,255 |
| 2020 | 29 | 1,486 | 43,221 | $1.2M | $451,086 |
Total Patients
3,238
Total Services
86,322
Medicare Billing
$920,681
Procedure Codes
76
All Medicare Procedures & Services
76 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 33 | 3,120 | $127,920 | $57,790 | 45.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 170 | 334 | $67,802 | $22,332 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 53 | 92 | $26,496 | $9,271 | 35.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $7,770 | $2,857 | 36.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 14 | 38 | $6,460 | $2,289 | 35.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 49 | 91 | $5,460 | $1,125 | 20.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 26 | 62 | $372.00 | $364.56 | 98.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 42 | 3,720 | $152,520 | $63,559 | 41.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 186 | 347 | $70,441 | $22,499 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 70 | 105 | $30,240 | $10,760 | 35.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 24 | 54 | $23,112 | $6,837 | 29.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $8,510 | $3,252 | 38.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 20 | 32 | $5,440 | $2,057 | 37.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 21 | 69 | $5,106 | $1,954 | 38.3% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 19 | 20 | $4,400 | $1,717 | 39.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 11 | 26 | $4,316 | $1,650 | 38.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 66 | 130 | $7,800 | $1,572 | 20.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 21 | 79 | $4,187 | $1,184 | 28.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 26 | 67 | $402.00 | $198.33 | 49.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 15 | 516 | $1,548 | $49.05 | 3.2% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2022 | 11 | 27 | $108.00 | $23.50 | 21.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 43 | 6,304 | $245,820 | $98,329 | 40.0% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2021 | 14 | 4,061 | $105,568 | $27,704 | 26.2% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 34 | 186 | $77,694 | $25,495 | 32.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 108 | 226 | $62,569 | $24,741 | 39.5% |
About Dr. Jack Jacoub, M.D
Dr. Jack Jacoub, M.D is a Internal Medicine healthcare provider based in Fountain Valley, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528016318.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jack Jacoub, M.D has received a total of $15,734 in payments from pharmaceutical and medical device companies, with $104.77 received in 2024. These payments were reported across 819 transactions from 81 companies. The most common payment nature is "Food and Beverage" ($15,307).
As a Medicare-enrolled provider, Jacoub has provided services to 3,238 Medicare beneficiaries, totaling 86,322 services with total Medicare billing of $920,681. Data is available for 4 years (2020–2023), covering 76 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Fountain Valley, CA
- Active Since 05/04/2006
- Last Updated 05/26/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1528016318
Products in Payments
- KEYTRUDA (Biological) $851.36
- OPDIVO (Biological) $706.92
- Imbruvica (Drug) $634.36
- IMBRUVICA (Drug) $478.06
- OCTAGAM (Biological) $352.00
- Lenvima (Drug) $342.01
- GILOTRIF (Drug) $320.52
- XTANDI (Drug) $310.12
- Senza Spinal Cord Stimulation System (Device) $294.76
- Cabometyx (Drug) $291.02
- Kyprolis (Biological) $278.05
- TAGRISSO (Drug) $270.14
- MEKINIST (Drug) $265.32
- CALQUENCE (Drug) $252.66
- Bavencio (Biological) $252.58
- NINLARO (Drug) $240.29
- FOUNDATIONONE (Device) $213.69
- EMPLICITI (Biological) $204.44
- Nplate (Biological) $197.69
- ELIQUIS (Drug) $189.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Fountain Valley
Truong-Sinh Leduc, M.d, M.D
Internal Medicine — Payments: $274,359
Internal Medicine $274,359
Rufina Pamela Mae Miel, Md, MD
Internal Medicine — Payments: $83,665
Internal Medicine $83,665
Dr. Janet Pan, M.d, M.D
Internal Medicine — Payments: $46,647
Internal Medicine $46,647
Pete Pow-Anpongkul
Internal Medicine — Payments: $26,930
Internal Medicine $26,930
Dr. Samarjit Singh, Md, MD
Internal Medicine — Payments: $25,901
Internal Medicine $25,901
Dr. Hoang Nguyen, M.d, M.D
Internal Medicine — Payments: $19,529
Internal Medicine $19,529